Search

Your search keyword '"Harada, Hitoshi"' showing total 457 results
Start Over Author "Harada, Hitoshi"
457 results on '"Harada, Hitoshi"'

2. The totally mechanical Collard technique for cervical esophagogastric anastomosis reduces anastomotic stricture compared with triangular anastomosis in minimally invasive esophagectomy with gastric conduit reconstruction through the retrosternal route: a propensity score-matched study

Author

Goto, Hironobu, Oshikiri, Taro, Koterazawa, Yasufumi, Sawada, Ryuichiro, Ikeda, Taro, Harada, Hitoshi, Urakawa, Naoki, Hasegawa, Hiroshi, Kanaji, Shingo, Yamashita, Kimihiro, Matsuda, Takeru, and Kakeji, Yoshihiro

Published
2024
Full Text
View/download PDF

7. Open left diaphragm method enables safe surgery with a good visual field in a laparoscopic transhiatal approach for esophagogastric junction adenocarcinoma laparoscopic transhiatal reconstruction via an open left diaphragm method

Author

Kanaji, Shingo, Urakawa, Naoki, Harada, Hitoshi, Shimada, Atsushi, Koterazawa, Yasufumi, Sawada, Ryuichiro, Goto, Hironobu, Hasegawa, Hiroshi, Yamashita, Kimihiro, Matsuda, Takeru, Oshikiri, Taro, and Kakeji, Yoshihiro

Published
2024
Full Text
View/download PDF

14. Predictive factors for refractory anastomotic stricture after cervical triangular anastomosis with gastric conduit reconstruction through the posterior mediastinum in minimally invasive esophagectomy

Author

Saiga, Hiroshi, Oshikiri, Taro, Goto, Hironobu, Koterazawa, Yasufumi, Kato, Takashi, Adachi, Yukari, Takao, Toshitatsu, Sawada, Ryuichiro, Harada, Hitoshi, Urakawa, Naoki, Hasegawa, Hiroshi, Kanaji, Shingo, Yamashita, Kimihiro, Matsuda, Takeru, Kodama, Yuzo, and Kakeji, Yoshihiro

Published
2024
Full Text
View/download PDF

19. Laparoscopic Endoscopic Cooperative Surgery Using Open-Window Suturing Technique for Treating Non-ampullary Superficial Duodenal Neoplasms Located on the Pancreatic Side

Author

Kanaji, Shingo, Morita, Yoshinori, Kudo, Takuya, Yamada, Kouta, Kato, Takashi, Sakai, Arata, Takao, Toshitatsu, Sawada, Ryuichiro, Harada, Hitoshi, Urakawa, Naoki, Goto, Hironobu, Hasegawa, Hiroshi, Yamashita, Kimihiro, Matsuda, Takeru, Oshikiri, Taro, Toyonaga, Takashi, Kodama, Yuzo, and Kakeji, Yoshihiro

Published
2022
Full Text
View/download PDF

26. Proposed modification of the eighth edition of the AJCC-ypTNM staging system of esophageal squamous cell cancer treated with neoadjuvant chemotherapy: Unification of the AJCC staging system and the Japanese classification

Author

Oshikiri, Taro, Goto, Hironobu, Kato, Takashi, Sawada, Ryuichiro, Harada, Hitoshi, Urakawa, Naoki, Hasegawa, Hiroshi, Kanaji, Shingo, Yamashita, Kimihiro, Matsuda, Takeru, Fujino, Yasuhiro, Tominaga, Masahiro, and Kakeji, Yoshihiro

Published
2022
Full Text
View/download PDF

36. Impact of Tumor Size on Survival Outcome in Esophageal Squamous Cell Carcinoma After Esophagectomy Following Neoadjuvant Chemotherapy

Author

Koterazawa, Yasufumi, primary, Oshikiri, Taro, additional, Goto, Hironobu, additional, Kato, Takashi, additional, Sawada, Ryuichiro, additional, Harada, Hitoshi, additional, Urakawa, Naoki, additional, Hasegawa, Hiroshi, additional, Kanaji, Shingo, additional, Yamashita, Kimihiro, additional, Matsuda, Takeru, additional, and Kakeji, Yoshihiro, additional

Published
2023
Full Text
View/download PDF

37. Effectiveness of long-term tube feeding intervention in preventing skeletal muscle loss after minimally invasive esophagectomy

Author

Kato, Takashi, primary, Oshikiri, Taro, additional, Koterazawa, Yasufumi, additional, Goto, Hironobu, additional, Sawada, Ryuichiro, additional, Harada, Hitoshi, additional, Urakawa, Naoki, additional, Hasegawa, Hiroshi, additional, Kanaji, Shingo, additional, Yamashita, Kimihiro, additional, Matsuda, Takeru, additional, and Kakeji, Yoshihiro, additional

Published
2023
Full Text
View/download PDF

39. Protocol for a phase II study to evaluate the efficacy and safety of nivolumab as a postoperative adjuvant therapy for patients with esophageal cancer treated with preoperative docetaxel, cisplatin plus 5-fluorouracil treatment (PENTAGON trial).

Author

Goto, Hironobu, Oshikiri, Taro, Kato, Takashi, Nagatani, Yoshiaki, Funakoshi, Yohei, Koterazawa, Yasufumi, Sawada, Ryuichiro, Harada, Hitoshi, Urakawa, Naoki, Hasegawa, Hiroshi, Kanaji, Shingo, Yamashita, Kimihiro, Matsuda, Takeru, Minami, Hironobu, and Kakeji, Yoshihiro

Subjects
NIVOLUMAB, CISPLATIN, IPILIMUMAB, DOCETAXEL, ADJUVANT chemotherapy, ESOPHAGEAL cancer, NEOADJUVANT chemotherapy, CETUXIMAB
Abstract

Background: In Japan, preoperative adjuvant chemotherapy followed by surgical resection is the standard treatment for patients with locally advanced esophageal squamous cell carcinoma. However, the risk of recurrence after surgical resection remains high. Although a randomized controlled trial evaluating the efficacy of nivolumab, a fully human monoclonal anti-programmed death 1 antibody, as postoperative adjuvant therapy after neoadjuvant chemoradiotherapy and surgery established its superior efficacy as adjuvant therapy, the efficacy for patients who received preoperative adjuvant chemotherapy has not been demonstrated. This study aims to elucidate the efficacy and safety of nivolumab as postoperative adjuvant therapy for patients with esophageal squamous cell carcinoma after preoperative adjuvant chemotherapy with docetaxel and cisplatin plus 5-fluorouracil followed by surgical resection. Methods: This study is a multi-institutional, single-arm, Phase II trial. We plan to recruit 130 esophageal squamous cell carcinoma patients, who have undergone preoperative adjuvant chemotherapy with docetaxel and cisplatin plus 5-fluorouracil followed by surgical resection. If the patient did not have a pathological complete response, nivolumab is started as a postoperative adjuvant therapy within 4–16 weeks after surgery. The nivolumab dose is 480 mg/day every four weeks. Nivolumab is administered for up to 12 months. The primary endpoint is disease-free survival; the secondary endpoints are overall survival, distant metastasis-free survival, and incidence of adverse events. Discussion: To our knowledge this study is the first trial establishing the efficacy of nivolumab as postoperative adjuvant therapy for patients with esophageal squamous cell carcinoma after preoperative adjuvant chemotherapy with docetaxel and cisplatin plus 5-fluorouracil followed by surgical resection. In Japan, preoperative adjuvant chemotherapy followed by surgery is a well-established standard treatment for resectable, locally advanced esophageal squamous cell carcinoma. Therefore, developing an effective postoperative adjuvant therapy has been essential for improving oncological outcomes. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

46. Supplementary Materials and Methods from E7386, a Selective Inhibitor of the Interaction between β-Catenin and CBP, Exerts Antitumor Activity in Tumor Models with Activated Canonical Wnt Signaling

Author

Yamada, Kazuhiko, primary, Hori, Yusaku, primary, Inoue, Satoshi, primary, Yamamoto, Yuji, primary, Iso, Kentaro, primary, Kamiyama, Hiroshi, primary, Yamaguchi, Atsumi, primary, Kimura, Takayuki, primary, Uesugi, Mai, primary, Ito, Junichi, primary, Matsuki, Masahiro, primary, Nakamoto, Kazutaka, primary, Harada, Hitoshi, primary, Yoneda, Naoki, primary, Takemura, Atsushi, primary, Kushida, Ikuo, primary, Wakayama, Naomi, primary, Kubara, Kenji, primary, Kato, Yu, primary, Semba, Taro, primary, Yokoi, Akira, primary, Matsukura, Masayuki, primary, Odagami, Takenao, primary, Iwata, Masao, primary, Tsuruoka, Akihiko, primary, Uenaka, Toshimitsu, primary, Matsui, Junji, primary, Matsushima, Tomohiro, primary, Nomoto, Kenichi, primary, Kouji, Hiroyuki, primary, Owa, Takashi, primary, Funahashi, Yasuhiro, primary, and Ozawa, Yoichi, primary

Published
2023
Full Text
View/download PDF

47. Data from E7386, a Selective Inhibitor of the Interaction between β-Catenin and CBP, Exerts Antitumor Activity in Tumor Models with Activated Canonical Wnt Signaling

Author

Yamada, Kazuhiko, primary, Hori, Yusaku, primary, Inoue, Satoshi, primary, Yamamoto, Yuji, primary, Iso, Kentaro, primary, Kamiyama, Hiroshi, primary, Yamaguchi, Atsumi, primary, Kimura, Takayuki, primary, Uesugi, Mai, primary, Ito, Junichi, primary, Matsuki, Masahiro, primary, Nakamoto, Kazutaka, primary, Harada, Hitoshi, primary, Yoneda, Naoki, primary, Takemura, Atsushi, primary, Kushida, Ikuo, primary, Wakayama, Naomi, primary, Kubara, Kenji, primary, Kato, Yu, primary, Semba, Taro, primary, Yokoi, Akira, primary, Matsukura, Masayuki, primary, Odagami, Takenao, primary, Iwata, Masao, primary, Tsuruoka, Akihiko, primary, Uenaka, Toshimitsu, primary, Matsui, Junji, primary, Matsushima, Tomohiro, primary, Nomoto, Kenichi, primary, Kouji, Hiroyuki, primary, Owa, Takashi, primary, Funahashi, Yasuhiro, primary, and Ozawa, Yoichi, primary

Published
2023
Full Text
View/download PDF

48. Supplementary Table S2 from E7386, a Selective Inhibitor of the Interaction between β-Catenin and CBP, Exerts Antitumor Activity in Tumor Models with Activated Canonical Wnt Signaling

Author

Yamada, Kazuhiko, primary, Hori, Yusaku, primary, Inoue, Satoshi, primary, Yamamoto, Yuji, primary, Iso, Kentaro, primary, Kamiyama, Hiroshi, primary, Yamaguchi, Atsumi, primary, Kimura, Takayuki, primary, Uesugi, Mai, primary, Ito, Junichi, primary, Matsuki, Masahiro, primary, Nakamoto, Kazutaka, primary, Harada, Hitoshi, primary, Yoneda, Naoki, primary, Takemura, Atsushi, primary, Kushida, Ikuo, primary, Wakayama, Naomi, primary, Kubara, Kenji, primary, Kato, Yu, primary, Semba, Taro, primary, Yokoi, Akira, primary, Matsukura, Masayuki, primary, Odagami, Takenao, primary, Iwata, Masao, primary, Tsuruoka, Akihiko, primary, Uenaka, Toshimitsu, primary, Matsui, Junji, primary, Matsushima, Tomohiro, primary, Nomoto, Kenichi, primary, Kouji, Hiroyuki, primary, Owa, Takashi, primary, Funahashi, Yasuhiro, primary, and Ozawa, Yoichi, primary

Published
2023
Full Text
View/download PDF

49. Supplementary Tables from E7386, a Selective Inhibitor of the Interaction between β-Catenin and CBP, Exerts Antitumor Activity in Tumor Models with Activated Canonical Wnt Signaling

Author

Yamada, Kazuhiko, primary, Hori, Yusaku, primary, Inoue, Satoshi, primary, Yamamoto, Yuji, primary, Iso, Kentaro, primary, Kamiyama, Hiroshi, primary, Yamaguchi, Atsumi, primary, Kimura, Takayuki, primary, Uesugi, Mai, primary, Ito, Junichi, primary, Matsuki, Masahiro, primary, Nakamoto, Kazutaka, primary, Harada, Hitoshi, primary, Yoneda, Naoki, primary, Takemura, Atsushi, primary, Kushida, Ikuo, primary, Wakayama, Naomi, primary, Kubara, Kenji, primary, Kato, Yu, primary, Semba, Taro, primary, Yokoi, Akira, primary, Matsukura, Masayuki, primary, Odagami, Takenao, primary, Iwata, Masao, primary, Tsuruoka, Akihiko, primary, Uenaka, Toshimitsu, primary, Matsui, Junji, primary, Matsushima, Tomohiro, primary, Nomoto, Kenichi, primary, Kouji, Hiroyuki, primary, Owa, Takashi, primary, Funahashi, Yasuhiro, primary, and Ozawa, Yoichi, primary

Published
2023
Full Text
View/download PDF

50. Supplementary Figures from E7386, a Selective Inhibitor of the Interaction between β-Catenin and CBP, Exerts Antitumor Activity in Tumor Models with Activated Canonical Wnt Signaling

Author

Yamada, Kazuhiko, primary, Hori, Yusaku, primary, Inoue, Satoshi, primary, Yamamoto, Yuji, primary, Iso, Kentaro, primary, Kamiyama, Hiroshi, primary, Yamaguchi, Atsumi, primary, Kimura, Takayuki, primary, Uesugi, Mai, primary, Ito, Junichi, primary, Matsuki, Masahiro, primary, Nakamoto, Kazutaka, primary, Harada, Hitoshi, primary, Yoneda, Naoki, primary, Takemura, Atsushi, primary, Kushida, Ikuo, primary, Wakayama, Naomi, primary, Kubara, Kenji, primary, Kato, Yu, primary, Semba, Taro, primary, Yokoi, Akira, primary, Matsukura, Masayuki, primary, Odagami, Takenao, primary, Iwata, Masao, primary, Tsuruoka, Akihiko, primary, Uenaka, Toshimitsu, primary, Matsui, Junji, primary, Matsushima, Tomohiro, primary, Nomoto, Kenichi, primary, Kouji, Hiroyuki, primary, Owa, Takashi, primary, Funahashi, Yasuhiro, primary, and Ozawa, Yoichi, primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results